ESMO: BMS’s Opdivo Edges Merck & Co’s Keytruda In First-Line Advanced Gastroesophageal Cancers

Competition Will Be Fierce Between Checkpoint Inhibitors

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.